نتایج جستجو برای: motesanib

تعداد نتایج: 53  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2010
Peter J Rosen Christopher J Sweeney Dorothy J Park Darrin M Beaupre Hongjie Deng Ian M Leitch Poornima Shubhakar Min Zhu Kelly S Oliner Abraham Anderson Lorrin K Yee

PURPOSE This phase Ib study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AMG 102, a fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF), in combination with bevacizumab or motesanib in patients with advanced solid tumors. EXPERIMENTAL DESIGN Patients with treatment-refractory advanced solid tumors were sequentially en...

2014
Ahmad Ebadi Nima Razzaghi-Asl Sara Shahabipour Ramin Miri

Vascular endothelial growth factor receptor-2 (VEGFR-2); a cell surface receptor for vascular endothelial growth factors, is a key pharmacological target involved in the cell proliferation/angiogenesis. It has been revealed that VEGFR-2 induces proliferation through activation of the extracellular signal-regulated kinases pathway. In this regard, targeting the VEGFR-2 has been considered as an ...

2014
Michael B. Bass Bin Yao Yong-Jiang Hei Yining Ye Gerard J. Davis Michael T. Davis Barbara A. Kaesdorf Sabrina S. Chan Scott D. Patterson Jose Luis Perez-Gracia

[This corrects the article DOI: 10.1371/journal.pone.0108048.].

2014
Yi-Jun Wang Yun-Kai Zhang Rishil J. Kathawala Zhe-Sheng Chen

The phenomenon of multidrug resistance (MDR) has attenuated the efficacy of anticancer drugs and the possibility of successful cancer chemotherapy. ATP-binding cassette (ABC) transporters play an essential role in mediating MDR in cancer cells by increasing efflux of drugs from cancer cells, hence reducing the intracellular accumulation of chemotherapeutic drugs. Interestingly, small-molecule t...

Vascular endothelial growth factor receptor-2 (VEGFR-2); a cell surface receptor for vascular endothelial growth factors, is a key pharmacological target involved in the cell proliferation/angiogenesis. It has been revealed that VEGFR-2 induces proliferation through activation of the extracellular signal-regulated kinases pathway. In this regard, targeting the VEGFR-2 has been considered as an ...

Vascular endothelial growth factor receptor-2 (VEGFR-2); a cell surface receptor for vascular endothelial growth factors, is a key pharmacological target involved in the cell proliferation/angiogenesis. It has been revealed that VEGFR-2 induces proliferation through activation of the extracellular signal-regulated kinases pathway. In this regard, targeting the VEGFR-2 has been considered as an ...

Journal: :iranian journal of pharmaceutical research 0
ahmad ebadi medicinal and natural products chemistry research center, shiraz university of medical sciences, shiraz, iran. department of medicinal chemistry, school of pharmacy, shiraz university of medical sciences, shiraz, iran nima razzaghi asl department of medicinal chemistry, school of pharmacy, ardabil university of medical sciences. sara shahabipour medicinal and natural products chemistry research center, shiraz university of medical sciences, shiraz, iran ramin miri medicinal and natural products chemistry research center, shiraz university of medical department of medicinal chemistry, school of pharmacy, shiraz university of medical sciences, shiraz, iran 2) medicinal & natural products chemistry research center, shiraz university of medical sciences,

vascular endothelial growth factor receptor-2 (vegfr-2); a cell surface receptor for vascular endothelial growth factors, is a key pharmacological target involved in the cell proliferation/angiogenesis. it has been revealed that vegfr-2 induces proliferation through activation of the extracellular signal-regulated kinases pathway. in this regard, targeting the vegfr-2 has been considered as an ...

Journal: :Journal of Experimental & Clinical Cancer Research 2010

2013
Barbara Jarząb

Radioiodine treatment constitutes the most effective therapeutic option of advanced differentiated thyroid cancer. Unfortunately, about 30% cancers do not show radioiodine uptake or do not respond to therapy. Thyrosine kinase inhibitors (TKI), among them axitinib, cabozantinib, lenvatinib, motesanib, pazopanib, sorafenib, sunitynib and vandetanib, constitute a new group of drugs implemented to ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید